Why Are Exicure Shares Trading At All Time Low?

by Vandana Singh, Benzinga Editor

November 16, 2021 8:26 AM | 1 min read |

Exicure Inc XCUR has filed a Form 12b-25 with the U.S. SEC in connection with its Form 10-Q for the period ended September 30, 2021.
On November 9, 2021, the Audit Committee of the Company's Board of Directors was notified of a claim regarding alleged improprieties for its XCUR-FXN preclinical program for Friedreich's ataxia.
The Audit Committee has retained external counsel to conduct an internal investigation of the claim.
The Company requires additional time to complete certain disclosures and procedures, including disclosures relating to the internal investigation.
Related Link: Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients.
Price Action: XCUR shares are down 23.4% at $0.82 during the premarket session on the last check Tuesday.

Posted In: Biotech News Penny Stocks Short Ideas Health Care Movers Trading Ideas General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.